Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?

被引：14

作者：

Fazio, Nicola ^{[1
,3
]}

La Salvia, Anna ^{[2
]}

机构：

[1] European Inst Oncol IEO, IRCCS, Div Gastrointestinal Med Oncol & Neuroendocrine Tu, Milan, Italy

[2] Natl Inst Hlth ISS, Natl Ctr Drug Res & Evaluat, Rome, Italy

[3] European Inst Oncol, Div Gastrointestinal Med Oncol & Neuroendocrine Tu, Via Ripamonti 435, I-20141 Milan, Italy

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2023年 / 37卷 / 05期

关键词：

Precision medicine; GEP-NENs; actionable tissue targets; liquid biopsy; theragnostics; CELL LUNG-CANCER; CLINICAL-PRACTICE GUIDELINES; POSITIVE SOLID TUMORS; OPEN-LABEL; ROVALPITUZUMAB TESIRINE; PHASE; 1/2; MTOR; EXPRESSION; SOMATOSTATIN; DABRAFENIB;

D O I：

10.1016/j.beem.2023.101794

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Precision medicine describes a target-related approach to tailoring diagnosis and treatment of the individual patient. While this personalized approach is revoluzionizing many areas of oncology, it is quite late in the field of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), in which there are few molecular alterations to be therapeutically targeted. We critically reviewed the current evidence about precision medicine in GEP NENs, focusing on potential clinically relevant actionable targets for GEP NENs, such as the mTOR pathway, MGMT, hypoxia markers, RET, DLL-3, and some general agnostic targets. We analysed the main investigational approaches with solid and liquid biopsies. Furthermore, we reviewed a model of precision medicine more specific for NENs that is the theragnostic use of radionuclides. Overall, currently no true predictive factors for therapy have been validated so far in GEP NENs, and the personalized approach is based more on clinical thinking within a NEN-dedicated multidisciplinary team. However, there is a robust background to suppose that precision medicine, with the theragnostic model will yield new insights in this context soon. (c) 2023 Elsevier Ltd. All rights reserved.

引用

页数：13

共 118 条

[1] miRNAs as potential game-changers in melanoma: A comprehensive review [J].

Abd-Allah, Gamil M. ;

Ismail, Ahmed ;

El-Mahdy, Hesham A. ;

Elsakka, Elsayed G. E. ;

El-Husseiny, Ahmed A. ;

Abdelmaksoud, Nourhan M. ;

Salman, Aya ;

Elkhawaga, Samy Y. ;

Doghish, Ahmed S. .

PATHOLOGY RESEARCH AND PRACTICE, 2023, 244

[2] Convergence of Precision Oncology and Liquid Biopsy in Non-Small Cell Lung Cancer [J].

Al-Obeidi, Ebaa ;

Riess, Jonathan W. ;

Malapelle, Umberto ;

Rolfo, Christian ;

Gandara, David R. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (03) :475-487

[3] Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids [J].

Alcala, N. ;

Leblay, N. ;

Gabriel, A. A. G. ;

Mangiante, L. ;

Hervas, D. ;

Giffon, T. ;

Sertier, A. S. ;

Ferrari, A. ;

Derks, J. ;

Ghantous, A. ;

Delhomme, T. M. ;

Chabrier, A. ;

Cuenin, C. ;

Abedi-Ardekani, B. ;

Boland, A. ;

Olaso, R. ;

Meyer, V ;

Altmuller, J. ;

Le Calvez-Kelm, F. ;

Durand, G. ;

Voegele, C. ;

Boyault, S. ;

Moonen, L. ;

Lemaitre, N. ;

Lorimier, P. ;

Toffart, A. C. ;

Soltermann, A. ;

Clement, J. H. ;

Saenger, J. ;

Field, J. K. ;

Brevet, M. ;

Blanc-Fournier, C. ;

Galateau-Salle, F. ;

Le Stang, N. ;

Russell, P. A. ;

Wright, G. ;

Sozzi, G. ;

Pastorino, U. ;

Lacomme, S. ;

Vignaud, J. M. ;

Hofman, V ;

Hofman, P. ;

Brustugun, O. T. ;

Lund-Iversen, M. ;

de Montpreville, V. Thomas ;

Muscarella, L. A. ;

Graziano, P. ;

Popper, H. ;

Stojsic, J. ;

Deleuze, J. F. .

NATURE COMMUNICATIONS, 2019, 10 (1)

[4] Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors [J].

Ali, Greta ;

Boldrini, Laura ;

Capodanno, Alessandra ;

Pelliccioni, Serena ;

Servadio, Adele ;

Crisman, Giuliana ;

Picchi, Alessandro ;

Davini, Federico ;

Mussi, Alfredo ;

Fontanini, Gabriella .

EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2011, 2 (05) :787-792

[5] Should temozolomide be used on the basis of O6-methylguanine DNA methyltransferase status in patients with advanced neuroendocrine tumors? A systematic review and meta-analysis [J].

Aliaga, P. Trillo ;

Spada, F. ;

Peveri, G. ;

Bagnardi, V. ;

Fumagalli, C. ;

Laffi, A. ;

Rubino, M. ;

Gervaso, L. ;

Rocco, E. Guerini ;

Pisa, E. ;

Curigliano, G. ;

Fazio, N. .

CANCER TREATMENT REVIEWS, 2021, 99

[6]

[Anonymous], 2019, A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas, V26, P391

[7] ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers [J].

Augustyn, Alexander ;

Borromeo, Mark ;

Wang, Tao ;

Fujimoto, Junya ;

Shao, Chunli ;

Dospoy, Patrick D. ;

Lee, Victoria ;

Tan, Christopher ;

Sullivan, James P. ;

Larsen, Jill E. ;

Girard, Luc ;

Behrens, Carmen ;

Wistuba, Ignacio I. ;

Xie, Yang ;

Cobb, Melanie H. ;

Gazdar, Adi F. ;

Johnson, Jane E. ;

Minna, John D. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (41) :14788-14793

[8] Clinical and Translational Research Challenges in Neuroendocrine Tumours [J].

Barriuso, Jorge ;

Lamarca, Angela .

CURRENT MEDICINAL CHEMISTRY, 2020, 27 (29) :4823-4839

[9] Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Baudin, E. ;

Caplin, M. ;

Garcia-Carbonero, R. ;

Fazio, N. ;

Ferolla, P. ;

Filosso, P. L. ;

Frilling, A. ;

de Herder, W. W. ;

Hoersch, D. ;

Knigge, U. ;

Korse, C. M. ;

Lim, E. ;

Lombard-Bohas, C. ;

Pavel, M. ;

Scoazec, J. Y. ;

Sundin, A. ;

Berruti, A. .

ANNALS OF ONCOLOGY, 2021, 32 (04) :439-451

[10]

BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X

← 1 2 3 4 5 6 7 8 9 10 →